Introduction
============

Gastric cancer remains the fourth most common cancer and the second leading cause of cancer-related mortality worldwide, contributing to a significant burden of disease, particularly in developing countries [@B1]. Epidemiological studies have identified many risk factors for gastric cancer, such as*Helicobacter pylori* infection, high intake of salt-preserved foods, tobacco smoking and pernicious anemia [@B2]. However, only a fraction of individuals exposed to these factors develop gastric cancer during their lifetime, which suggests that genetic susceptibility plays an important role in gastric carcinogenesis.

The complement system is a collection of serum proteins that are integral to inflammatory processes and to innate immune responses to infection. Based on the epidemiological and experimental data, it has been established that chronic inflammation is involved in tumor onset, promotion and progression [@B3], [@B4]. Over recent years, studies have suggested an insidious relationship between gastric cancer and chronic inflammation, especially resulting from the infection with *Helicobacter pylori* [@B5], [@B6]. Chronic inflammation orchestrates a tumor-supporting microenvironment that is an indispensable participant in the neoplastic process [@B7]. Considering the connection of complement system, innate immunity and chronic inflammation, complement proteins may play an important role in carcinogenesis. Studies have suggested that complements facilitate innate immune against cancer through direct tumor lysis or complement-independent cytotoxicity (CDC) [@B8]. Studies have indicated that complement C5a in the tumor microenvironment promoted tumor growth by the myeloid-derived suppressor (MDS) cell-mediated immunosuppression [@B9], [@B10]. Taken as a whole, the complement system may have a dual effect on the process of carcinogenesis [@B11].

Complement receptor 1 (CR1/CD35) is a type I membrane-bound glycoprotein that belongs to the regulators of complement activity (RCA) family [@B12], [@B13]. Acting as the receptor for C3b and C4b, CR1 expressed on various cell types, including lymphocytes, erythrocytes, phagocytes, and dendritic cells [@B14]. As an inhibitor of complement activation, *CR1* has been reported to be involved in the pathogenesis of several cancers [@B15], [@B16].

Previously, we investigated 13 tag SNPs in *CR1* gene and found that rs7525160 polymorphism was significantly associated with the susceptibility to non-small cell lung cancer (NSCLC) [@B17]. In this study, we performed a case-control study in a Chinese population to test the hypothesis that the tag SNPs of *CR1* contribute to the susceptibility to gastric cancer.

Materials and Methods
=====================

Study subjects
--------------

The present case-control study comprised 500 patients with gastric cancer and 500 healthy controls Patients were recruited between Jan 2008 and Dec 2013 from Hebei United University affiliated Tangshan Gongren Hospital and Tangshan Renmin Hospital in China, without receiving any radiotherapy or chemotherapy at the time of recruitment and no restrictions in regard to age, gender. The response rate for patients was 94%. All subjects were genetic unrelated Han Chinese. The eligible patients were primary histopathologically confirmed and previously untreated by radiotherapy and chemotherapy. Patients with previous malignancy or metastasized cancer from other organs were excluded. The controls were randomly selected from cancer-free population from the community conducted in the same region during the same period when patients were recruited. The selection criteria for the controls included no prior history of malignancy, and control subjects were frequency-matched to the patients by age (±5 years) and gender. At recruitment, written informed consent was obtained from each subject. This study was approved by the Institutional Review Board of Hebei United University.

Selection of Tag SNPs and SNP genotyping
----------------------------------------

Based on the Chinese population data from HapMap database, we used HaploView 4.2 program to select the candidate tag SNPs with an r^2^ threshold of 0.8 and minor allele frequency (MAF) greater than 1%. Under this criteria, totally 11 tag SNPs were selected. Additionally, we added two potential functional SNPs, rs9429942 and rs6691117 [@B18], [@B19]. Therefore, we included 13 SNPs in our study, which represents common genetic variants in Chinese population.

Genotyping was performed at Bomiao Tech (Beijing, China) using iPlex Gold Genotyping Assay and Sequenom MassArray (Sequenom, San Diego, CA, USA). Sequenom\'s MassArray Designer was used to design PCR and extension primers for each SNP. The PCR primers used are available upon request. Genotyping quality control consisted of no-temple control samples for allele peaks and verifying consistencies in genotype calls of 2% randomly selected duplicate samples. In addition, two control samples were included on each plate as genotyping controls for inter-plate reproducibility. Hardy-Weinberg Equilibrium (HWE) was also evaluated in unrelated controls.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS16.0 statistical software package (version16.0, SPSS, Chicago, IL). The chi-square goodness of fit test was used for any deviation from Hardy-Weinberg equilibrium in controls. The χ^2^test was used to examine the differences in demographic distributions and genotype frequencies between cases and controls. We estimated the cancer risk associated with CR1 tag SNPs by odds ratios (ORs) and 95% confidence intervals (CIs) computed by logistic regression model adjusted for age, gender, and smoking status. All statistical tests were two-sided and differences were taken as significant when*P*-value was \< 0.05. Gene-gene and gene-smoking interactions were analyzed by open resource generalized multifactor dimensionality reduction (GMDR) software package (version 0.9) and Quanto [@B20], [@B21]. For given sample size, the power to detect statistically significant associations was calculated using online power and sample size calculator for unmatched case-control study (<http://www.stat.ubc.ca> ).

Results
=======

Subject characteristics
-----------------------

The frequency distributions of selected characteristics of participants were shown in Table [1](#T1){ref-type="table"}. No significant statistical differences in the sex (*P* = 0.407), age (*P*= 0.317) and smoking status (*P*= 0.652) distributions were observed between cases and controls, which suggesting that the frequency matching was adequate.

Association of individual Tag SNP and gastric cancer risk
---------------------------------------------------------

Table [2](#T2){ref-type="table"} showed the position and minor allele frequency (MAF) of 13 tag SNPs of CR1 in HapMap database among Chinese population. Besides the rs9429782 polymorphism, the genotype distributions of other 12 SNPs in controls accorded with Hardy-Weinberg equilibrium (*P \>*0.05). Therefore, we excluded the rs9429782 from further analysis. As depicted in Table [3](#T3){ref-type="table"}, these 12 tag SNPs were genotyped in all subjects including the 500 patients with gastric cancer and 500 healthy controls. The genotype frequency of rs9429942 T\>C among the cases was significantly different from those among controls (χ^2^ = 10.415, *P*= 0.001). There was no statistical difference of genotype distributions between gastric cancer cases and healthy controls for other 11 tag SNPs (*P*\> 0.05). Multivariate logistic regression analysis was used to assess the association of 12 tag SNPs of *CR1* with the risk of gastric cancer (Table [3](#T3){ref-type="table"}). For rs9429942 T\>C polymorphism, the CT genotype was significantly associated with a decreased risk of gastric cancer (OR = 0.12; 95% CI = 0.03-0.50; *P*= 0.004) compared with the homozygote TT. Based on our sample size, our study had 93% power to detect the significant association of rs9429942 polymorphism with the risk of cancer risk with OR of 0.12. For rs7525160 G\>C variant, when compared with GG genotype, CG genotype was associated with a decreased risk of gastric cancer (OR = 0.7; 95% CI = 0.53-0.93; *P*= 0.013); but CC genotype was not (OR = 1.13; 95% CI = 0.80-1.62; *P*= 0.485). For other 10 tag SNPs of *CR1*, our data did not show any association with the susceptibility to gastric cancer in our study population (*P\>*0.05). When stratified by smoking status, our results did not show any interaction of Tag SNPs of *CR1* with smoking status contribute to the risk of developing gastric cancer (data not shown).

Association of SNP-SNP interactions and gastric cancer risk
-----------------------------------------------------------

GMDR was used to evaluate gene-gene interaction of 12 SNPs from *CR1* gene (Table [4](#T4){ref-type="table"}). Although the SNP rs7525160 in *CR1* had the highest testing balanced accuracy of 54.88% among 12 SNPs, the result was not significant (*P* = 0.055). Similarly, the rs4844600 G\>A and rs10494885 C\>T were shown to be the best two-way model with a testing balance accuracy of 52.92%, however, the interaction was not significant (*P*= 0.055). Three-way interaction model among rs75422544 C\>A, rs10494885 C\>T and rs7525160 G\>C showed the maximum testing balance accuracy (56.07%) and cross validation consistency (7/10). The three-way interaction was significant (*P*= 0.011).

Discussion
==========

Genetic background plays an important role in the development of gastric cancer, which is a multifactorial genetic disease resulting from gene-environment interaction [@B22]. Over recent years, genome-wide association studies (GWAS) have identified multiple genetic loci associated with gastric cancer risk [@B23]-[@B25]. In addition, much effort in case-control studies has been spent in searching for cancer susceptibility genes, such as genes coding for inflammatory mediators [@B7], DNA repair [@B26], apoptosis [@B27] and carcinogen metabolism [@B28]. In a *Nature Immunology* article, Rutkowski and his colleges reviewed that complement proteins might facilitate the process of carcinogenesis by increasing activity of mitogenic signaling pathways, inducing cellular proliferation, and promoting immunosupression [@B29]. Acting as a negative regulator of the complement cascade, CR1 was also involved in the development of various cancers. In the present study, we investigated the association of 13 tag SNPs of *CR1* with the risk of gastric cancer in Chinese population and found that rs9429942 CT genotype was associated with a decreased risk of gastric cancer (OR = 0.12; 95% CI = 0.03-0.50; *P*= 0.004), compared with the TT genotype. Furthermore, GMDR analysis revealed that a three-loci significant interaction among rs75422544, rs10494885 and rs7525160 of *CR1* gene with the highest test accuracy of 56.07% (*P*= 0.011). To the best of our knowledge, it is first report that *CR1* genetic variations contribute to the risk of developing gastric cancer.

Gastric cancer is characterized by a prominent inflammatory component [@B30]. As a fundamental component of innate immunity, complement is an enzymatic cascade that results in the release of pro-inflammatory anaphylatoxins, including most notably the anaphylatoxins C3a and C5a [@B31], [@B32]. Complement system has long been thought to fight against cancer by exerting the effects of immunosurveillance in the immunologic microenvironment of tumors [@B10]. However, tumor cells are protected from complement-mediated injury by membrane-bound complement regulatory proteins (mCRPs) that are often up-regulated on tumor cells [@B33]-[@B35]. These mCRPs consists of CR1, complement factor H (CFH), decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46), and homologous restriction factor 20 (HRF29, CD59), which can inhibit complement activation by blocking the complement cascade at the C3 activation stage or preventing formation of the membrane attack complex (MAC) [@B33], [@B36]. Therefore, it is desirable to combine anti-tumor monoclonal antibodies (mAb) immunotherapy or tumor vaccines with the blocking of mCRPs in cancer immunotherapy [@B37]. Considering the important role of mCRPs in carcinogenesis, it is reasonable that genetic variants in mCRPs might affect the susceptibility to certain cancers. For instance, recent evidence has showed that *CFH* Y402H polymorphism interacted with cigarette smoking to effect the development of lung cancer in the Chinese population [@B38]. Studies also showed that the CR1 3650A\>G Rsa I polymorphism in exon 22 was associated with the risk of gallbladder cancer [@B16] and the rs7525160 G\>C polymorphism contributed to the risk of non-small cell lung cancer [@B17].

In the present study, we provided the evidence that the CT genotype of *CR1* rs9429942 was strongly associated with protective effect against gastric cancer in Chinese population. As depicted in the table [2](#T2){ref-type="table"}, rs9429942 T\>C variant located in 5\' near *CR1* gene. Teeranaipong *et al*evaluated the association of rs9429942 T\>C variant with the erythrocyte CR1 expression level in 24 healthy Thai subjects and found that TT genotype contribute to higher erythrocyte CR1 level [@B18]. The lower expression may effect on the rate of clearance of immune complexes from circulation[@B39]. The concentration of immune complexes in advanced gastric cancer patients was significantly higher than that in normal subjects[@B40]. This may explain the role of rs9429942 in the development of gastric cancer. However, the function of rs9429942 T\>C variant still need be verified in large study. Whatever, these studies at least illustrated that *CR1* rs9429942 might be a good candidate genetic susceptibility locus for certain diseases. Meanwhile, we also paid attention to another interesting result that the CG genotype of *CR1* rs7525160 was significantly associated with a decreased risk of gastric cancer compared with homozygote GG, while the CC genotype was not. Based on the current data, rs7525160 G\>C can not be considered as a risk factor for gastric cancer. However, in our previous study, we reported that rs7525160 CC and CG genotype were related to an increased risk of developing NSCLC in Chinese population [@B17]. The discrepancy may result from the different tumor site, therefore more convincing studies still need be done in the future.

Based on our findings, we could speculate about the role of the *CR1* gene for the pathogenesis of gastric cancer. As a receptor for C3b/C4b, CR1 functioned both as a regulator of complement activation and as a vehicle for immune complexes (ICs) clearance [@B41]. By reversibly binding to C3b and C4b and further inactivating C3 and C5 covertases, CR1 involved in the classical and alternate pathway [@B42]. In addition, CR1 serves as a necessary cofactor in the proteolytic cleavage of C3b and C4b by complement factor I (CFI) [@B43]. The genetic variations in *CR1* gene has been reported to affect CR1 copy number on erythrocytes, which in turn correlates with the rate of ICs clearance from the circulation [@B39], [@B44].

Considering the ubiquity of genetic interactions in the pathogenesis of complex diseases, the identification and characterization of susceptible genes or polymorphisms require a thorough understanding of gene-gene interactions [@B45]. Over recent years, gene-gene interaction factors have been taken into account in studies of gastric cancer carcinogenesis [@B46], [@B47]. In our study, multiple interactions of genetic variants, including rs75422544, rs10494885 and rs7525160 were observed for gastric cancer. This desirable result would encourage us to explore genetic susceptibility conferred by co-stimulatory molecules in gastric cancer in the future.

In conclusion, our data provided the new evidence of the role of *CR1* in the development of gastric cancer. However, some limitations should be addressed. Due to the relatively small sample size, further study still need to be conducted to confirm the findings of the present study. Furthermore, the biological functions of *CR1* polymorphism also need to be investigated.
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###### 

Distributions of selected characteristics in cases and control subjects

  Variables            Cases (n=500)          Controls (n=500)                
  -------------------- --------------- ------ ------------------ ----- ------ -------
  **Sex**                                                                     0.407
  Male                 357             71.4                      344   68.8   
  Female               143             28.6                      156   31.2   
  **Age**                                                                     0.317
  ≤50                  141             28.2                      156   31.2   
  51-60                149             29.8                      157   31.4   
  \>60                 210             42.0                      187   37.4   
  **Smoking status**                                                          0.652
  Non-smoker           294             58.8                      302   60.4   
  Smoker               206             41.2                      198   39.6   

^a^Two-sided χ^2^ test.

###### 

Primary information of genotyped SNPs of CR1

  Gene and locus   Rs number    Contig position   Location        Base change   MAF in controls   *P* for HWE test   Calling rate (%)
  ---------------- ------------ ----------------- --------------- ------------- ----------------- ------------------ ------------------
  CR1 1q32         rs7525160    1186193           5\' near gene   G/C           0.42              0.910              100
                   rs9429942    1186409           5\' near gene   T/C           0.02              0.928              99.3
                   rs9429782    1187134           5\' near gene   G/T           0.24              \<0001             100
                   rs4844600    1197086           E60D            G/A           0.39              0.999              100
                   rs6656401    1209828           Intron          G/A           0.04              0.720              99.9
                   rs3886100    1256906           Intron          A/G           0.48              0.420              99.7
                   rs11118167   1299933           Intron          T/C           0.14              0.992              99.4
                   rs6691117    1300710           I2065V          A/G           0.17              0.920              99.5
                   rs3818361    1302747           Intron          C/T           0.37              0.923              100
                   rs7542544    1304002           Intron          C/A           0.49              0.623              100
                   rs2296160    1313099           I2419A          C/T           0.37              0.579              99.6
                   rs17048010   1318668           Intron          T/C           0.20              0.986              99.0
                   rs10494885   1332968           3\'near gene    C/T           0.39              0.960              99.5

MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium.

###### 

Genotype frequencies of CR1 among cases and controls and their association with gastric cancer

  -------------------------------------------------------------------------------------------------------------
  CR1\         Controls (n=500)          Cases (n=500)   OR (95% CI)^a^   *P*value                      
  Genotypes                                                                                             
  ------------ ------------------ ------ --------------- ---------------- ---------- ------------------ -------
  rs7525160                                                                                             

  GG           167                33.4                   189              37.8       1.00 (ref.)        

  CG           248                49.6                   199              39.8       0.70(0.53-0.93)    0.013

  CC           85                 17.0                   112              22.4       1.13(0.80-1.62)    0.485

  rs3886100                                                                                             

  GG           124                24.8                   129              25.8       1.00 (ref.)        

  AG           235                47.0                   260              52.0       1.06 (0.78-1.44)   0.711

  AA           141                28.2                   111              22.2       0.77 (0.54-1.09)   0.135

  rs11118167                                                                                            

  TT           371                74.2                   377              75.4       1.00 (ref.)        

  CT           119                23.8                   109              21.8       0.91(0.67-1.23)    0.530

  CC           10                 2.0                    14               2.8        1.32(0.58-3.02)    0.513

  rs10494885                                                                                            

  CC           187                37.4                   172              34.4       1.00 (ref.)        

  CT           240                48.0                   236              47.2       1.05(0.80-1.38)    0.735

  TT           73                 14.6                   92               18.4       1.40(0.96-2.03)    0.079

  rs7542544                                                                                             

  CC           136                27.2                   109              21.8       1.00 (ref.)        

  AC           239                47.8                   260              52.0       1.33(0.98-1.81)    0.069

  AA           125                25.0                   131              26.2       1.29(0.91-1.84)    0.155

  rs6691117                                                                                             

  AA           344                68.8                   347              69.4       1.00 (ref.)        

  AG           143                28.6                   138              27.6       0.97(0.73-1.28)    0.807

  GG           13                 2.6                    15               3.0        1.11(0.52-2.38)    0.786

  rs6656401                                                                                             

  GG           465                93.0                   475              95.0       1.00 (ref.)        

  AG           35                 7.0                    25               5.0        0.70(0.41-1.19)    0.183

  rs2296160                                                                                             

  CC           193                38.6                   214              42.8       1.00 (ref.)        

  CT           244                48.8                   230              46.0       0.86(0.66-1.12)    0.269

  TT           63                 12.6                   56               11.2       0.81(0.54-1.23)    0.327

  rs9429942                                                                                             

  TT           483                96.6                   498              99.6       1.00 (ref.)        

  CT           17                 3.4                    2                0.4        0.12(0.03-0.50)    0.004

  rs4844600                                                                                             

  GG           184                36.8                   199              39.8       1.00 (ref.)        

  AG           239                47.8                   242              48.4       0.94(0.72-1.23)    0.644

  AA           77                 15.4                   59               11.8       0.72(0.49-1.08)    0.110

  rs3818361                                                                                             

  CC           197                39.4                   210              42.0       1.00 (ref.)        

  CT           237                47.4                   235              47.0       0.93(0.72-1.22)    0.618

  TT           66                 13.2                   55               11.0       0.80(0.53-1.20)    0.282

  rs17048010                                                                                            

  TT           317                63.4                   318              63.6       1.00 (ref.)        

  CT           163                32.6                   162              32.4       0.99(0.77-1.29)    0.940

  CC           20                 4.0                    20               4.0        1.01(0.53-1.91)    0.985
  -------------------------------------------------------------------------------------------------------------

^a^Data were calculated by unconditional logistic regression and adjusted for gender, age and smoking status.

###### 

Summary of GMDR SNP-SNP interaction results for CR1 gene

  Models                             Training Bal. Acc (%)   Testing Bal. Acc. (%)   *P* value   Cross-validation Consistency
  ---------------------------------- ----------------------- ----------------------- ----------- ------------------------------
  Rs7525160                          54.90                   54.88                   0.055       10/10
  Rs4844600, rs10494885              56.67                   52.92                   0.055       5/10
  Rs7542544, rs10494885, rs7525160   59.27                   56.07                   0.011       7/10

GMDR, generalized multifactor dimensionality reduction; Training Bal. Acc, training balance accuracy; Testing Bal. Acc, testing balance accuracy.
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